Last reviewed · How we verify
Aspirin 81 enteric coated tablet daily
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of thromboxane A2 and preventing platelet aggregation.
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of thromboxane A2 and preventing platelet aggregation. Used for Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke), Acute coronary syndrome, Atrial fibrillation for stroke prevention.
At a glance
| Generic name | Aspirin 81 enteric coated tablet daily |
|---|---|
| Also known as | Aspirin |
| Sponsor | University of Florida |
| Drug class | Antiplatelet agent / Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase-1 (COX-1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin acetylates serine residues on COX-1 and COX-2 enzymes, permanently blocking their catalytic activity. This prevents the synthesis of thromboxane A2 in platelets, which is a key mediator of platelet activation and clot formation. At low doses (81 mg), aspirin preferentially affects platelet function, making it effective for antiplatelet therapy without significantly affecting other prostaglandin-dependent processes.
Approved indications
- Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke)
- Acute coronary syndrome
- Atrial fibrillation for stroke prevention
Common side effects
- Gastrointestinal bleeding
- Dyspepsia
- Nausea
- Hemorrhagic stroke
- Allergic reactions
Key clinical trials
- Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty (PHASE2)
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (PHASE2)
- Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease (NA)
- Aspirin (ASA) Therapy and Preeclampsia Prevention (PHASE4)
- Impact of COX2 on Sera Biomarkers From Obese Subjects (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin 81 enteric coated tablet daily CI brief — competitive landscape report
- Aspirin 81 enteric coated tablet daily updates RSS · CI watch RSS
- University of Florida portfolio CI